Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buparlisib + carboplatin
- Development stage
- Phase 1
- Lead developer
- Adlai Nortye
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Buparlisib (BKM120) plus carboplatin is an investigational combination therapy studied primarily in advanced solid tumors. Buparlisib is an orally available pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor that targets all class IA PI3K paralogues (p110α, β, and δ), disrupting the PI3K/AKT signaling pathway involved in cancer cell growth and survival. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. The rationale for combining these agents is based on preclinical evidence that PI3K inhibition can sensitize tumor cells to platinum-based chemotherapy. This combination has been evaluated in phase I clinical trials for patients with advanced solid tumors to determine safety, tolerability, and recommended dosing[1][2]. Preliminary results indicate manageable toxicity and some antitumor activity.
- Other names
- BKM120 + carboplatinbuparlisib + carboplatin
02
Targets
DNAPIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)TUBB (Tubulin (alpha and beta subunits))PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CD (Phosphatidylinositol 3-kinase delta)
Beyond the preview
Go deeper on buparlisib + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buparlisib + carboplatin.